Chiasm gliomas in pediatric patients. Part 1. Сlinical manifestations
- Authors: Serova N.K.1, Alyaeva O.O.1
-
Affiliations:
- Burdenko National medical research center for Neurosurgery
- Issue: Vol 19, No 1 (2024)
- Pages: 55-62
- Section: Reviews
- URL: https://journals.rcsi.science/1993-1859/article/view/254283
- DOI: https://doi.org/10.17816/rpoj624691
- ID: 254283
Cite item
Abstract
Chiasm gliomas are very important heterogeneous group of tumors manifesting in the first and second decades of life and is the second leading cause of blindness in children with neurosurgical pathology. It is a benign, slow-growing piloid astrocytoma, accounting for 1–5% of intracranial gliomas in children. The incidence of neurofibromatosis type 1 among patients with chiasm glioma ranges from 7 to 60%. The location of the tumor is determined based on ophthalmological symptoms, neuroimaging data (MRI), and surgical findings. The initial growth of the tumor occurs in the anterior visual pathway structures (optic nerves, chiasm, optic tracts) and leads to ophthalmological symptoms, which are dominant in the clinical manifestations of the disease. Chiasm damage may occur in one or both optic nerves, in one or both optic tracts. Damage to the chiasm manifests as bitemporal heteronymous hemianopsia. Moreover, the spread of the tumor to the optic nerves is accompanied by decreased visual acuity. Damage to the optic tract is manifested by homonymous hemianopia and normal visual acuity. However, isolated damage to the optic tract is uncommon and usually occurs with chiasm and optic nerve lesions; hence, visual disturbances are more complex. Lesions in the optic nerve fibers in the chiasm and optic nerves/tracts lead to primary descending atrophy of the optic nerves. Papilledema with optic nerve atrophy indicates occlusive hydrocephalus. Delayed diagnosis of the disease affects treatment results.
Full Text
##article.viewOnOriginalSite##About the authors
Natalya K. Serova
Burdenko National medical research center for Neurosurgery
Author for correspondence.
Email: NSerova@nsi.ru
ORCID iD: 0000-0003-0148-7298
SPIN-code: 5079-8064
MD, Dr. Sci. (Medicine), Рrofessor
Russian Federation, MoscowOksana O. Alyaeva
Burdenko National medical research center for Neurosurgery
Email: AlyaevaOO@nsi.ru
ORCID iD: 0009-0007-6157-8382
SPIN-code: 7606-4984
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowReferences
- Yousefi O, Azami P, Sabahi M, et al. Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(19):4781. doi: 10.3390/cancers14194781
- Tang Y, Gutmann DH. Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects. Cancer Manag Res. 2023;(15):667–681. doi: 10.2147/CMAR.S362678
- Serova NK, editor. Clinical neuroophthalmology. Neurosurgical aspects. Tver: Triada; 2011. P. 133–178. (In Russ).
- Rosser T, Packer RJ. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol. 2002;17(8):630–637;discussion 646–651. doi: 10.1177/088307380201700815
- Korones DN, Padowski J, Factor BA, Constine LS. Do children with optic pathway tumors have an increased frequency of other central nervous system tumors? Neuro Oncol. 2003;5(2):116–120. doi: 10.1093/neuonc/5.2.116
- Lourie GL, Osborne DR, Kirks DR. Involvement of posterior visual pathways by optic nerve gliomas. Pediatr Radiol. 1986;16(4):271–274. doi: 10.1007/BF02386860
- Shah JR, Patkar DP, Pungavkar SA, Parmer H. Extensive gliomas of visual tract in a patient of neurofibromatosis-I. Indian J Pediatr. 2000;67(12):939–940. doi: 10.1007/BF02723963
- Liu GT, Brodsky MC, Phillips PC, et al. Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol. 2004;137(3):407–414. doi: 10.1016/j.ajo.2003.09.055
- Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14(6):790–797. doi: 10.1093/neuonc/nos076
- Segal L, Darvish-Zargar M, Dilenge ME, et al. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS. 2010;14(2):155–158. doi: 10.1016/j.jaapos.2009.11.020
- Prada CE, Hufnagel RB, Hummel TR, et al. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1. J Pediatr. 2015;167(4):851.e1–856.e1. doi: 10.1016/j.jpeds.2015.07.001
- Trevisson E, Cassina M, Opocher E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. J Neurooncol. 2017;134(2):279–287. doi: 10.1007/s11060-017-2517-6
- Sellmer L, Farschtschi S, Marangoni M, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2018;13(1):62. doi: 10.1186/s13023-018-0811-9
- Listernick R, Charrow J, Tomita T, Goldman S. Carboplatin therapy for optic pathway tumors in children with neurofibromatosis type-1. J Neurooncol. 1999;45(2):185–190. doi: 10.1023/a:1006338322266
- Grill J, Laithier V, Rodriguez D, et al. When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr. 2000;159(9):692–696. doi: 10.1007/s004310000531
- Chateil JF, Soussotte C, Pédespan JM, et al. MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol. 2001;74(877):24–31. doi: 10.1259/bjr.74.877.740024
- Guillamo JS, Créange A, Kalifa C, et al. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients. Brain. 2003;126(Pt 1):152–160. doi: 10.1093/brain/awg016
- Singhal S, Birch JM, Kerr B, et al. Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child. 2002;87(1):65–70. doi: 10.1136/adc.87.1.65
- Azizi AA, Walker DA, Liu JF, et al. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol. 2021;23(1):100–111. doi: 10.1093/neuonc/noaa153
- Shofty B, Ben Sira L, Constantini S. Neurofibromatosis 1-associated optic pathway gliomas. Childs Nerv Syst. 2020;36(10):2351–2361. doi: 10.1007/s00381-020-04697-1
- Gayre GS, Scott IU, Feuer W, et al. Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuroophthalmol. 2001;21(1):1–7. doi: 10.1097/00041327-200103000-00001
- Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology. 2004;111(3):568–577. doi: 10.1016/j.ophtha.2003.06.008
- Wan MJ, Ullrich NJ, Manley PE, et al. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016;129(1):173–178. doi: 10.1007/s11060-016-2163-4
- Rassi SZ, Ospina LH, Bochereau A, et al. Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas. Doc Ophthalmol. 2019;139(2):137–149. doi: 10.1007/s10633-019-09703-9
- Bowman R, Walters B, Smith V, et al. Visual outcomes and predictors in optic pathway glioma: a single centre study. Eye (Lond). 2023;37(6):1178–1183. doi: 10.1038/s41433-022-02096-1
- Kinori M, Armarnik S, Listernick R, et al. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More. Am J Ophthalmol. 2021;(221):91–96. doi: 10.1016/j.ajo.2020.03.053
- Jost SC, Ackerman JW, Garbow JR, et al. Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol. 2008;38(12):1293–1299. doi: 10.1007/s00247-008-1003-x
- Takenchi H, Kabuto M, Sato K, Kubota T. Chiasmal gliomas with spontaneous regression: proliferation and apoptosis. Childs Nerv Syst. 1997;13(4):229–233. doi: 10.1007/s003810050073
- Rubtsova IV, Parsa KF, Hoyt IF. Spontaneous regression of familial optic nerve glioma in a boy with presumed neurofibromatosis type 1 (Recklinghausen disease). The Russian Annals of Ophthalmology. 1998;114(3):48–51. (In Russ).
- Valiakhmetova EF, Mazerkina NA, Medvedeva OA, et al. Optic pathway gliomas associated with neurofibromatosis type I in children. Pediatric Hematology/Oncology and Immunopathology. 2019;18(4):29–38. (In Russ). doi: 10.24287/1726-1708-2019-18-4-29-38
- Brzowski AE, Bazan C 3rd, Mumma JV, Ryan SG. Spontaneous regression of optic glioma in a patient with neurofibromatosis. Neurology. 1992;42(3 Pt 1):679–681. doi: 10.1212/wnl.42.3.679
- Pruzan NL, de Alba Campomanes A, Gorovoy IR, Hoyt C. Spontaneous Regression of a Massive Sporadic Chiasmal Optic Pathway Glioma. J Child Neurol. 2015;30(9):1196–1198. doi: 10.1177/0883073814546686
- Ryzhova MV, Galstyan SA, Telysheva EN. Significance of DNA methylation assessment in the morphological diagnosis of brain tumours. Arkhiv Patologii. 2022;84(3):65–75. (In Russ). doi: 10.17116/patol20228403165
- Iannaccone A, McCluney RA, Brewer VR, et al. Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol. 2002;105(1):63–81. doi: 10.1023/a:1015719803719
- Kelly JP, Leary S, Khanna P, Weiss AH. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology. 2012;119(6):1231–1237. doi: 10.1016/j.ophtha.2011.12.035
- Dotto PF, Berezovsky A, Cappellano AM, et al. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1. Doc Ophthalmol. 2018;136(3):177–189. doi: 10.1007/s10633-018-9635-0
- Yokoyama S, Takayama K, Sueda M, et al. Optic nerve glioma manifesting as intratumoral hemorrhage in a pregnant woman — case report. Neurol Med Chir (Tokyo). 2003;43(11):559–562. doi: 10.2176/nmc.43.559
- Arrese I, Sarabia R, Zamora T. Chiasmal haemorrhage secondary to glioma with unusual MRI appearance. Neurocirugia (Astur). 2014;25(3):136–139. doi: 10.1016/j.neucir.2013.11.001
- Walrath JD, Engelbert M, Kazim M. Magnetic resonance imaging evidence of optic nerve glioma progression into and beyond the optic chiasm. Ophthalmic Plast Reconstr Surg. 2008;24(6):473–475. doi: 10.1097/IOP.0b013e31818beed9